Table 3 Estimation of total annual costs of MS patients in the country by drug therapy lines in 2019 ($ PPP)
From: Economic burden of multiple sclerosis: a cross-sectional study in Iran
Drug Therapy Lines | Number of Patients in Iran | DMCs | DNMCs | ICs | COI | ||||
|---|---|---|---|---|---|---|---|---|---|
Mean | % | Mean | % | Mean | % | Mean | % | ||
First line | 51,230 | 45,635,352 | 46.42 | 35,568,105 | 36.18 | 17,103,715 | 17.40 | 98,307,172 | 52.31 |
Second line | 21,956 | 63,842,200 | 71.24 | 16,442,699 | 18.35 | 9,334,509 | 10.42 | 89,619,408 | 47.69 |
Total | 73,186 | 117,931,925 | 59.21 | 53,754,387 | 26.99 | 27,484,272 | 13.80 | 199,170,584 | 100 |